Empirical evidence for low reproducibility indicates low pre-study odds

Nature Reviews Neuroscience

Volumn 14, Issue 12, 2013, Pages 877-

  Button, Katherine S ^a   Ioannidis, John P A ^b   Mokrysz, Claire ^a   Nosek, Brian A ^c   Flint, Jonathan ^d   Robinson, Emma S J ^a   Munafò, Marcus R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EFFECT SIZE; LETTER; MEDICAL RESEARCH; NEUROSCIENCE; PRIORITY JOURNAL; REPRODUCIBILITY;

HUMANS; NEUROSCIENCES; SAMPLE SIZE;

EID: 84888132174     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn3475-c6     Document Type: Letter

References (5)

1. Nutt, D. J., King, L. A. & Nicholls, D. E. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Rev. Neurosci. 14, 577-585 (2013).
2. Stewart, A. M. & Kalueff, A. V. Controlled substances and innovation of biomedicine: a preclinical perspective. Nature Rev. Neurosci. http://dx. doi. org/10. 1038/nrn3530c1 (2013).
3. The Misuse of Drugs Act 1971 (Temporary Class Drug) Order 2013. No. 1294. legislation. gov. uk [online], http://www. legislation. gov. uk/uksi/2013/1294/pdfs/ uksi-20131294-en. pdf (2013).
4. Ettrup, A. et al. Preclinical safety assessment of the 5HT2A receptor agonist PET radioligand [11C]Cimbi36. Mol. Imaging Biol. 15, 376-383 (2013).
5. UK Home Office. New psychoactive substances: G8 statement on collection and sharing of data. gov. uk [online], https://www. gov. uk/government/ publications/ new-psychoactive-substances-g8statement-on-collection-and-sharing- of-data (2013).